tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Pacira Pharmaceuticals Stockholders Approve Amended Incentive Plan
PremiumCompany AnnouncementsPacira Pharmaceuticals Stockholders Approve Amended Incentive Plan
1M ago
Pacira announces new long-term follow-up data from Phase 1 trial on PCRX-201
Premium
The Fly
Pacira announces new long-term follow-up data from Phase 1 trial on PCRX-201
1M ago
Pacira reports inducement grants under Nasdaq listing rule
Premium
The Fly
Pacira reports inducement grants under Nasdaq listing rule
2M ago
Pacira sees FY25 revenue $725M-$765M, consensus $752.9M
PremiumThe FlyPacira sees FY25 revenue $725M-$765M, consensus $752.9M
3M ago
Pacira announces new data from Phase 1 study of PCRX-201
Premium
The Fly
Pacira announces new data from Phase 1 study of PCRX-201
3M ago
Pacira to present new data on PCRX-201
Premium
The Fly
Pacira to present new data on PCRX-201
3M ago
Pacira price target raised to $28 from $25 at Truist
PremiumThe FlyPacira price target raised to $28 from $25 at Truist
4M ago
Positive Outlook for Pacira Pharmaceuticals Amid Exparel Settlement and Strategic Growth Initiatives
Premium
Ratings
Positive Outlook for Pacira Pharmaceuticals Amid Exparel Settlement and Strategic Growth Initiatives
4M ago
Pacira price target raised to $26 from $22 at RBC Capital
Premium
The Fly
Pacira price target raised to $26 from $22 at RBC Capital
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100